Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

NCT04158739 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Cytarabine
BIOLOGICAL: Flotetuzumab

Sponsor

Children's Oncology Group

Collaborators

[object Object]